Odyssey Health, Inc.

ODYY: 10-K · periodic report

Odyssey Health's fiscal 2026 10-K carries a going-concern qualification: the company has never generated product revenue, posted a $5.73M net loss, and holds only $147,859 in current assets against $12.28M in current liabilities. The company defaulted on a Mast Hill convertible note at its August 2026 maturity and failed to maintain required share reserves. A October 23, 2026 Global Amendment extended all Mast Hill note maturities to January 31, 2027 and waived certain defaults, but Odyssey states it does not have funds to repay at the new maturity and expects to be in default absent restructuring, extension, or new financing. Additional red flags include material weaknesses in internal control over financial reporting, a down-tier from OTCQB to the OTCID Basic Market effective October 1, 2026, variable-price convertible notes requiring more shares than the 500M authorized, and penny stock status — all pointing to severe dilution and potential bankruptcy risk for ODYY shareholders.

SEC 10-K•3h ago

ODYY: 10-Q · periodic report

Odyssey Health reported a net loss of $3.3 million for the nine months ended April 30, 2026, driven by $3.1 million in financing costs and $1 million in interest expense, despite a $1.5 million gain from the change in fair value of derivative liabilities. The company generated no revenue, holding only $297,806 in cash against $10.1 million in current liabilities, resulting in a $9.7 million working capital deficit. Management disclosed substantial doubt about the company’s ability to continue as a going concern, stating that continued existence depends on raising additional capital. The filing also revealed material weaknesses in internal controls, specifically citing insufficient resources and inadequate segregation of duties in finance and accounting. In subsequent events, the company disclosed the termination of its exclusive license for the BreastCheck technology after counterparty NeuRX Health failed to obtain required approvals from Davion Healthcare. Additionally, the company dissolved its Australian subsidiary and extended the maturity dates on several convertible debt instruments with Mast Hill Fund and LGH Investments.

SEC 10-Q•4mo ago

ODYY: 8-K · debt financing

Odyssey Health, Inc. (OTC: ODYY) entered into Amendment No. 12 to its convertible promissory note with LGH Investments, LLC, extending the maturity date to September 30, 2026. The original note, dated April 5, 2021, carries a principal balance of $1.05 million. This is the twelfth amendment to the instrument, indicating a prolonged period of debt restructuring or rollover. The extension provides the company with additional time to manage liquidity without immediate repayment pressure, though it signals continued reliance on convertible debt financing.

SEC 8-K•5mo ago

ODYY: 8-K · material agreement

On May 6, 2026, Odyssey Health, Inc. received a formal written notice from NeuRX Health, Inc. advising that NeuRX is in breach of its contractual obligations with Davion Healthcare Plc regarding the BreastCheck product. NeuRX failed to obtain Davion's required approval before sublicensing the product to Odyssey. As a result, the definitive agreement between Odyssey and NeuRX, dated October 14, 2025, and which closed on April 21, 2026, is immediately cancelled. This cancellation will likely disrupt Odyssey's plans to distribute and manufacture the BreastCheck product. Davion has advised NeuRX to require Odyssey to announce its withdrawal of previous public notifications about holding a sub-license for BreastCheck, to avoid misleading shareholders and the market.

SEC 8-K•5mo ago